Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and Other Viral Infections

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 5, 2003, Pages 372-381

  Wu, Jashin J ^a   Brentjens, Mathijs H ^b   Torres, Gisela ^b   Yeung Yue, Kimberly ^b   Lee, Patricia ^b   Tyring, Stephen K ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; FAMCICLOVIR; PENCICLOVIR; PLACEBO; PROBENECID; VALACICLOVIR;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSMENORRHEA; EPSTEIN BARR VIRUS; GENITAL HERPES; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; REVIEW; SKIN INFECTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VERTIGO; VIRUS INFECTION; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; TREATMENT OUTCOME; VALINE; VIRUS DISEASES;

EID: 0345059716     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-002-0140-3     Document Type: Review

References (67)

1. Hayden RG. Antimicrobial agents. In: Hardman JG, Limbirdeds LE, Eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996, pp 1191-1223.
2. Drake S, Taylor S, Brown D, et al. Improving the care of patients with genital herpes. BMJ 2000; 321:619-623.
3. Simmons A, Field HJ. Can HSV latency be conquered by current antiviral therapies? Sex Transin Infect 1998; 74:1-2.
4. Thackray AM, Field HJ. Comparison of effects of famciclovir and valacyclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob Agents Chemother 1996; 40:846-851.
5. Field HJ, Thackray AM. The effects of delayed onset chemotherapy using famciclovir and valacyclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 1995; 6:210-216.
6. Dobson AT, Little BB, Scott LL. Prevention of herpes simplex virus infection and latency by prophylactic treatment with acyclovir in a weanling mouse model. Am J Obstet Gynecol 1998; 179:527-532.
7. Field HJ, Tewarti D, Sutton D, et al. Comparison of efficacies of famciclovir and valacyclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995; 39:1114-1119.
8. Stein GE. Pharmacology of new antiherpes agents: Famciclovir and valacyclovir. J Am Pharm Assoc 1997; S37:157-163.
9. Littler E. Safety and efficacy issues of herpesvirus drugs. Antiviral Chem Chemother 1994; 5(Suppl 1):11-16.
10. Luber AD, Flaherty JF. Famciclovir for treatment of herpesvirus infections. Ann Pharmacother 1996; 30:978-985.
11. Ormrod D, Scott LJ, Perry CM. Valaciclovir: A review of its long-term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000; 59:839-863.
12. Valtrex® (valacyclovir hydrochloride) package insert, GlaxoSmithKline, ResearchTriangle Park, NC, October 2000.
13. Zovirax® (acyclovir) package insert, GlaxoSmithKline, Research-Triangle Park, NC, 2000.
14. De Bony F, Tod M, Bidault R, et al. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother 2002; 46:458-463.
15. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex Transm Dis 1997; 24:481-486.
16. Spruance SL, Tyring SK, Degregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-1735.
17. Tyring SK, Douglas JM, Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998; 134:185-191.
18. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomized, doubled-blind clinical trial. Genitourin Med 1997; 73:110-116.
19. Saiag P, Chastang C, Bertin I, et al. (1996) Efficacy, safety, and equivalence of 1000 mg once daily and 500 mg twice daily valaciclovir in recurrent genital herpes. Program and Abstracts of the 38th ICAAC, 15-18 September 1996, San Diego, CA, Abstr H-113.
20. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002; 34:958-962.
21. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
22. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984; 251:2103-2107.
23. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. J Infect Dis 1998; 178:603-610.
24. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo-controlled study of once daily therapy. Genitourin Med 1997; 73:105-109.
25. Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet Gynecol 1999; 94:103-106.
26. Mervi GJ, Jones CC, Mills J, et al. Long-term-acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. JAMA 1988; 260:201-206.
27. Baker DA, Safrin S, Deeter RG, et al. Nine year effectiveness of continuous suppressive therapy with acyclovir (ACV) in patients with recurrent genital herpes (RGH) [abstr. No. P220]. J Eur Acad Dermatol Venereol 1995; 5 Suppl. 1:S169.
28. Baker DA. Valacyclovir in the treatment of genital herpes and herpes zoster. Expert Opin Pharmacother 2002; 3:51-58.
29. Mann SL, Meyers JD, Holmes KK, et al. Prevalence and incidence of herpesvirus infections among homosexually active men. J Infect Dis 1984; 149:1026-1027.
30. Seigal D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections. The population-based AIDS in multiethnic neighborhoods study. JAMA 1992; 268:1702-1708.
31. Enzensberger R, Braun W, Judy C, et al. Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection 1991; 19:140-145.
32. McGrath BJ, Newman CL. Genital herpes simplex infections in patients with the acquired immunodeficiency syndrome. Pharmacotherapy 1994; 14:529-542.
33. Safrin S, Ashley R, Houlihan C, et al. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS 1991; 5:1107-1110.
34. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. Arch Dermatol 1993; 129:582-587.
35. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984; 310:1545-1550.
36. Lawrence AG, Bell AR. and the International Valaciclovir HSV Study Group. Valaciclovir for prevention of recurrent herpes simplex virus infection in HIV infected individuals-a double-blind controlled trial. 8th European Congress of Clinical Microbiology and Infectious Disease, Lausanne, Switzerland, 25-28 May, 1997.
37. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12-21.
38. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
39. Wald A, Warren T, Hu H, et al. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valacyclovir. Programs and Abstracts of the 38th ICAAC, San Diego, CA, 24-27 September 1998, Abstr H-82.
40. Corey L, Tyring S, Sacks S, et al. Once daily valacyclovir reduces transmission of genital herpes. 42nd ICAAC, San Diego, CA, 27 September 2002, Abstr 3874.
41. Tyring S. Single-day, oral valacyclovir in the treatment and prevention of cold sore lesions. Poster 31, Poster Session from the summer session of the American Academy of Dermatology, 2 July 2002, New York, NY, 2002.
42. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Dermatol Surg 2000; 26:50-54.
43. Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg 2002; 28:331-336.
44. Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin J Sport Med 1999; 9:86-90.
45. Dignani MC, Mykietiuk A, Michelet M, et al. Valacyclovir prophylaxis for the prevention of herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 2002; 29:263-267.
46. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcomes in herpes zoster-an observational study with valaciclovir. J Eur Acad Dermatol Venerol 2000; 14:23-33.
47. Whitley RJ, Shukla S, Crooks RJ, et al. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998; 178 Suppl. 1:S71-S75.
48. Smiley ML. International Valaciclovir Zoster Study Group. The efficacy and safety of valaciclovir for the treatment of herpes zoster. 33rd ICAAC; 17-20 October 1993, New Orleans, LA, Abstr 340.
49. Johnson RW, Crooks RJ. International Valaciclovir Zoster Study Group. The clinical efficacy of valaciclovir in the treatment of herpes zoster [abstract]. J Eur Acad Dermatol Venerol 1995; 5 Suppl. 1:S75.
50. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-1553.
51. Beutner K. Antivirals in the treatment of pain. J Geriatric Dermatol 1994; 6(Suppl 2):23A-28A.
52. Niimura M, Honda M, Nishikawa T, et al. Phase III study of valaciclovir hydrochloride tablets in patients with herpes zoster: double-blind comparative study with acyclovir tablets [in Japanese]. Rinsho Iyaku 1998; 14:2867-2902.
53. Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001; 34:138-142.
54. Grant DM, Mauskopf JA, Bell L, et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 1997; 17:333-341.
55. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863-869.
56. Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107:1507-1511.
57. Gatchel S. Use of famciclovir and valaciclovir in the treatment of viral keratitis. Clin Infect Dis 1996; 22:886.
58. Sund F, Wahlberg J, Eriksson BM. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir. J Clin Virol 2001; 23:107-111.
59. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-1470.
60. Vusirikala M, Wolff SN, Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 2001; 28:265-270.
61. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99:3050-3056.
62. Egan JJ, Carroll KB, Yonan N, et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 2002; 21:460-466.
63. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21:547-554.
64. Bech E, Lycke J, Gadeberg P, et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002; 58:31-36.
65. Fife KG, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of at least 6 years of chronic suppression with acyclovir. J Infect Dis 1994; 169:1338-1341.
66. Bell WR, Chulary JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997; 76:369-380.
67. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency. J Infect Dis 1998; 177:48-56.